| 今开：5.65 | 昨收：5.65 |
| 最高：5.68 | 最低：5.35 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：1.43263886E8 |
产业链观察04-09 20:31
#药闻简讯# 美国FDA已授予$Syros(SYRS)$ 他米巴罗汀与阿扎胞苷和维奈托克联合用于治疗新诊断的RARA过表达急性髓系白血病（AML）的快速通道资格。查看全文
SeekingBiotech04-09 23:04
$Syros(SYRS)$
SYRS announced that the FDA has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) with RARA overexpression as detected by an FDA approved test in ad...查看全文
Syros(SYRS)04-03 04:25
$Syros(SYRS)$ 144 Report of proposed sale of securities Accession Number: 0001973141-24-000207 Act: 33 Size: 4 KB 网页链接查看全文
Syros(SYRS)04-03 05:05
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040308 Size: 12 KB 网页链接查看全文
Syros(SYRS)04-03 05:05
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040320 Size: 12 KB 网页链接查看全文
Syros(SYRS)03-27 19:05
$Syros(SYRS)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-24-078195 Act: 33 Size: 66 KB 网页链接查看全文
Syros(SYRS)04-23 19:15
$Syros(SYRS)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-24-105892 Act: 34 Size: 556 KB 网页链接查看全文
Syros(SYRS)05-14 18:45
$Syros(SYRS)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-059068 Act: 34 Size: 7 MB 网页链接查看全文
Syros(SYRS)04-03 05:05
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040302 Size: 14 KB 网页链接查看全文
Syros(SYRS)04-06 04:35
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-042289 Size: 4 KB 网页链接查看全文
霸王意气尽2016-07-01 02:16
$Syros Pharmaceuticals, Inc. Common Stock(SYRS)$ Syros Pharmaceuticals：基因修復藥物研發
生命科學公司錫羅斯製藥（Syros Pharmaceuticals Inc）成立於 2013 年，首輪融資了 3,000 萬美元，2014 年底該公司完成 5,300 萬美元 B 輪融資，該公司的投資者包括中國知名的 CRO 公司——藥明康...查看全文
智通财经APP获悉，因塞特(INCY.US)已经终止了与Syros Pharmaceuticals(SYRS.US)在骨髓增生性肿瘤治疗方面的发现和研究合作。终止协议将在8月9日起60天内生效。 2018年1月，因塞特和Syros Pharmaceuticals首次签署了一项合作协议。作为合... 网页链接
$Syros(SYRS)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-059068 Act: 34 Size: 7 MB 网页链接
$Syros(SYRS)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-24-105892 Act: 34 Size: 556 KB 网页链接
$Syros(SYRS)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-105901 Act: 34 Size: 1 MB 网页链接
$Syros(SYRS)$ DEF 14A Other definitive proxy statements Accession Number: 0001193125-24-105876 Act: 34 Size: 1 MB 网页链接
$Syros(SYRS)$ PRE 14A Other preliminary proxy statements Accession Number: 0001193125-24-094755 Act: 34 Size: 1 MB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-042289 Size: 4 KB 网页链接
$Syros(SYRS)$ 144 Report of proposed sale of securities Accession Number: 0001973141-24-000211 Act: 33 Size: 4 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040289 Size: 12 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040297 Size: 8 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040302 Size: 14 KB 网页链接